Investing Profile

Ali Behbahani

VCInvestor

General Partner at New Enterprise Associates (NEA)

nea.com/team/ali-behbahani-mdPhiladelphia, Pennsylvania
Photo of Ali Behbahani, General Partner at New Enterprise Associates (NEA)

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
$50K - $50.0M
$25.0M
10
$5B
CompanyStageDateRound SizeTotal Raised
858 Therapeutics
Series ASep 2021$60M
$60M
Co-investors: Clare Ozawa (Versant Ventures)
Stablix
Series AJun 2021$63M
$63M
Co-investors: Carlo Rizzuto (Versant Ventures)
Spyglass Ophthalmics
Series BJan 2021$28M
$28M
Co-investors: Tak Cheung (New Enterprise Associates (NEA)), Cynthia Yee (Vensana Capital)
Monte Rosa Therapeutics
Series AMay 2020$33M
$130M
Co-investors: Andrew Schiff (Aisling Capital), Markus Warmuth (Versant Ventures), Alexander Mayweg (Versant Ventures)
Rotation Medical
Series BAug 2016$12M
$39M
Co-investors: Scott Weiner (Amzak Health Investors)
CRISPR Therapeutics
Funding RoundApr 2015$64M
Series BApr 2015$29M
Series AApr 2015$35M
$130M
Co-investors: Kurt von Emster (Abingworth), Simeon J. George (SR One)
Adaptimmune
Series ASep 2014$100M
$100M
Co-investors: David Mott (Mott Family Capital)
Acclarent
Series BDec 2005$25M
$86M
Co-investors: Rob Ward (Meritech Capital Partners)